As previously reported, Morgan Stanley upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with an unchanged price target of $45. The stock has been under substantial pressure, down around 40% in the last 6 months, despite what the firm considers to be better than expected results and a successful MOBI rollout, says the analyst, who also thinks the stock is “looking too cheap now.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes upgraded to Overweight from Equal Weight at Morgan Stanley
- Tandem Diabetes price target raised to $60 from $58 at Barclays
- Tandem Diabetes price target lowered to $40 from $43 at UBS
- Tandem Diabetes price target lowered to $56 from $57 at Canaccord
- Tandem Diabetes price target lowered to $37 from $39 at Baird